A Multi-Centre, International, Randomised, Vehicle Controlled, Parallel-Group, Double-Blinded Phase 2 Trial of BB2603 Topical Treatment in Subjects With Distal Subungual Onychomycosis (DSO) of the Toe nail
Latest Information Update: 16 Nov 2023
At a glance
- Drugs Terbinafine (Primary) ; Alcohol; Polihexanide
- Indications Onychomycosis
- Focus Therapeutic Use
- Sponsors Blueberry Therapeutics
Most Recent Events
- 13 Nov 2023 Primary endpoint has been met (Number of subjects with an Early Response for BB2603-10 versus vehicle), according to Blueberry Therapeutics.
- 13 Nov 2023 Results published in the Blueberry Therapeutics Media Release.
- 06 Jul 2023 Status changed from active, no longer recruiting to completed.